Abstract:Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.See Duran-Aniotz et al. (doi 10.1093/brain/awv401) for a scientific commentary on this article.Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.The aberrant accumulation of toxic protein aggregates is a key feature of many neurodegenerative diseases, including Huntington's disease, amyotrophic lateral sclerosis and Alzheimer's disease. As such, improving normal proteostatic mechanisms is an active target for biomedical research. Although they share common pathological features, protein aggregates form in different subcellular locations. N epsilon-lysine acetylation in the lumen of the endoplasmic reticulum has recently emerged as a new mechanism to regulate the induction of autophagy. The endoplasmic reticulum acetylation machinery includes AT-1/SLC33A1, a membrane transporter that translocates acetyl-CoA from the cytosol into the endoplasmic reticulum lumen, and ATase1 and ATase2, two acetyltransferases that acetylate endoplasmic reticulum cargo proteins. Here, we used a mutant form of alpha-synuclein to show that inhibition of the endoplasmic reticulum acetylation machinery specifically improves autophagy-mediated disposal of toxic protein aggregates that form within the secretory pathway, but not those that form in the cytosol. Consequently, haploinsufficiency of AT-1/SLC33A1 in the mouse rescued Alzheimer's disease, but not Huntington's disease or amyotrophic lateral sclerosis. In fact, intracellular toxic protein aggregates in Alzheimer's disease form within the secretory pathway while in Huntington's disease and amyotrophic lateral sclerosis they form in different cellular compartments. Furthermore, biochemical inhibition of ATase1 and ATase2 was also able to rescue the Alzheimer's disease phenotype in a mouse model of the disease. Specifically, we observed reduced levels of soluble amyloid-beta aggregates, reduced amyloid-beta pathology, reduced phosphorylation of tau, improved synaptic plasticity, and increased lifespan of the animals. In conclusion, our results indicate that N epsilon-lysine acetylation in the endoplasmic reticulum lumen regulates normal proteostasis of the secretory pathway; they also support therapies targeting endoplasmic reticulum acetyltransferases, ATase1 and ATase2, for a subset of chronic degenerative diseases.

Cathepsin L prevents the accumulation of alpha‐synuclein fibrils in the cell

Novel Cathepsin D Inhibitors Block the Formation of Hyperphosphorylated Tau Fragments in Hippocampus

Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity

Cathepsin D overexpression in the nervous system rescues lethality and A β 42 accumulation of cathepsin D systemic knockout in vivo

Activated Cathepsin L is Associated with the Switch from Autophagy to Apoptotic Death of SH-SY5Y Cells Exposed to 6-Hydroxydopamine

Alpha-synuclein preformed fibril-induced aggregation and dopaminergic cell death in cathepsin D overexpression and ZKSCAN3 knockout mice

Regulatory role of cathepsin L in induction of nuclear laminopathy in Alzheimer’s disease

Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity

Lysosomal Cysteine Peptidase Cathepsin L Protects Against Cardiac Hypertrophy Through Blocking AKT/GSK3β Signaling

Prosaposin Reduces α-Synuclein in Cells and Saposin C Dislodges it from Glucosylceramide-enriched Lipid Membranes

Effects of Lanthionine Ketimine-5-Ethyl Ester on the α-Synucleinopathy Mouse Model

Haplodeficiency Of Cathepsin D Does Not Affect Cerebral Amyloidosis And Autophagy In App/Ps1 Transgenic Mice

Improved Proteostasis in the Secretory Pathway Rescues Alzheimer’s Disease in the Mouse

Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome

Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease

α-synuclein buildup is alleviated via ESCRT-dependent endosomal degradation brought about by p38MAPK inhibition in cells expressing p25α

Negative Regulation of Cathepsins by {beta}-Amyloid

Cellular depletion of major cathepsin proteases reveals their concerted activities for lysosomal proteolysis

Inhibition of cathepsin L alleviates the microglia-mediated neuroinflammatory responses through caspase-8 and NF-κB pathways.

L116 Deletion in CSPα Promotes α-Synuclein Aggregation and Neurodegeneration

Microglial LRRK2-mediated NFATc1 attenuates α-synuclein immunotoxicity in association with CX3CR1-induced migration and the lysosome-initiated degradation